Latest news with #Alpenglow
Daily Mirror
6 days ago
- Automotive
- Daily Mirror
Hydrogen-powered hypercar with almost zero emissions debuts in UK
The Alpine Alpenglow concept car was on display at the annual motoring event in West Sussex and is a one-off concept car, but both its hydrogen powertrain and styling are set to inspire future Alpine road cars Petrolheads were treated to the sight of a £3million zero-emission hypercar at the Goodwood Festival of Speed, which roared into action for the first time on UK soil yesterday. Enthusiasts flocked to see the Alpine Alpenglow concept car at the iconic West Sussex motoring celebration. The striking vehicle operates on combusted hydrogen rather than traditional fuels or batteries – its emissions are almost non-existent. Though this Alpenglow model remains unique, it is paving the way for upcoming Alpine cars in both design and eco-friendly powertrain technology. Sporty aesthetics and a hybrid engine of French pedigree that mixes classic petrol with electric firepower are part of Alpine's ambitious plan for a line-up of new models valued north of the £1 million mark. Speaking about Alpine's innovation, Bruno Famin from Alpine Motorsports commented: "With the development of this brand new Hy6 V6 engine, we are demonstrating our commitment to hydrogen research, which could herald motorsport applications with high-performance levels. "The Alpenglow Hy6 concept is the perfect example of what is possible to achieve the essential step of reducing carbon emissions in motorsport." At Goodwood this year, an estimated 200,000 visitors had the opportunity to glimpse the future of racing with the high-octane spectacle of liquid hydrogen engines challenging the dominance of battery electric alternatives. The Alpenglow dazzled crowds when unveiled in 2022, serving as a vision for the trajectory of Alpine's automotive advancements. Building on the success of the first road-going prototype, powered by a 340bhp turbocharged 2.0-litre 4-cylinder engine, the Alpenglow Hy6 now boasts an all-new powertrain that more than doubles its predecessor's output. At its core lies a revolutionary 3.5-litre V6 engine, designed in-house by Alpine to optimise hydrogen combustion. This results in an impressive 544kW (740bhp), equating to over 150kW/l (210bhp/l), and positioning the Alpenglow among the performance elite. The concept's Specular Blue carbon fibre bodywork has been reworked, showcasing more aggressive lines. The spoiler is more pronounced and visible from the front, while the shark-fin has grown in size, proudly displaying the Alpine logo, hydrogen's chemical formula, and an eye-catching magenta to blue gradient that represents its combustion process. Beneath the bonnet, F1-inspired methodologies have been employed to hone the engine's key performance components. Antony Villain, Alpine's VP of Design, noted: "The adaptation of this V6 is a technical challenge, highlighted for all to see in a redesigned rear section. "Various elements of the concept's design are evolving, sculpted by the aerodynamic imperatives implied by its new performance, while visually evoking both speed and the virtuous aspects of hydrogen."
Yahoo
03-06-2025
- Business
- Yahoo
Molecular Instruments and Alpenglow Biosciences Partner to Advance 3D RNA Imaging in Intact Biological Samples
LOS ANGELES & SEATTLE, June 03, 2025--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the innovative HCR™ platform, and Alpenglow Biosciences, a leader in 3D light-sheet microscopy, are excited to announce a partnership that enables high-resolution, three-dimensional RNA imaging in intact biological specimens. By integrating MI's HCR™ Gold RNA-FISH assay with Alpenglow's 3Di™ Hybrid Open-Top Light-Sheet (HOTLS) fluorescent microscope, researchers gain access to a powerful, accessible workflow for visualizing molecular expression patterns in 3D while preserving the native architecture of their samples. This collaboration merges two state-of-the-art technologies into a seamless imaging solution. HCR™ Gold RNA-FISH provides highly specific and sensitive labeling of RNA targets in any sample, including thick tissues and whole-mount specimens. Additionally, the HCR™ platform's small DNA-based amplification reagents enable deep sample penetration and produce strong signals with minimal background, ensuring robust results even in challenging samples. Complementing this, Alpenglow's 3Di™ HOTLS system generates high-resolution 3D reconstructions across a broad range of sample sizes and formats, transforming labeled samples into rich, spatially resolved datasets. Alpenglow further enhances these insights with cutting-edge data processing and AI-driven analysis, enabling a deeper understanding of complex biological systems. "HCR™ products have long enabled researchers to see deeper – delivering gold-standard performance in thick and complex samples, from whole-mount embryos to cleared tissues," said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. "We pioneered protease-free sample preparation to preserve fine structure, and now, with Alpenglow, we're entering a new era: democratizing 3D molecular imaging for the translational community. By combining the precision of HCR™ Gold with the power of open-top light-sheet microscopy, we're opening a window into intact biology – making it possible to explore molecular organization in its native context, at scale." "We are excited to work with the team at Molecular Instruments," said Nick Reder, MD and CEO of Alpenglow Biosciences. "With their high-quality HCR™ Gold reagents and ability to penetrate deep tissue, along with our 3Di Instrument, we will bring a powerful new tool to customers seeking to understand the underlying biology of their tissue specimens with labeling of RNA targets. These tools working together will help researchers and drug development scientists to unlock insights within the tissue to help accelerate their scientific programs." Together, the two platforms eliminate the limitations of conventional 2D histology, which often relies on thin tissue sections and can obscure key biological context. This integrated approach empowers researchers to explore intact samples – such as embryos, organoids, and other delicate 3D structures – without disrupting their morphology. In doing so, scientists can uncover spatial patterns and cellular interactions that would otherwise be lost in serial sections. Designed for modern workflows, HCR™ Gold is fully compatible with tissue clearing and automation, ensuring reproducible, scalable performance across large studies. Alpenglow's 3Di™ HOTLS enhances this capability with a versatile imaging system that supports scan volumes up to 12.5 cm by 7 cm and features a 1 cm working distance – delivering high-throughput, adaptive imaging across diverse research applications. This joint solution is especially impactful in fields such as developmental biology, neuroscience, and immunology – areas where understanding molecular organization in 3D is critical to advancing scientific discovery. By combining the precision of HCR™ Gold with the advanced imaging capabilities of 3Di™ HOTLS, MI and Alpenglow Biosciences are offering deeper insights into complex systems and setting a new standard in molecular profiling. About Molecular Instruments Molecular Instruments® ( is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics. About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at View source version on Contacts Media Contact: Joyce YooAssociate Director of Marketingjoyce@ Steve PembertonSVP Commercial Developmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
03-06-2025
- Business
- Business Wire
Molecular Instruments and Alpenglow Biosciences Partner to Advance 3D RNA Imaging in Intact Biological Samples
LOS ANGELES & SEATTLE--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the innovative HCR™ platform, and Alpenglow Biosciences, a leader in 3D light-sheet microscopy, are excited to announce a partnership that enables high-resolution, three-dimensional RNA imaging in intact biological specimens. By integrating MI's HCR™ Gold RNA-FISH assay with Alpenglow's 3Di™ Hybrid Open-Top Light-Sheet (HOTLS) fluorescent microscope, researchers gain access to a powerful, accessible workflow for visualizing molecular expression patterns in 3D while preserving the native architecture of their samples. Experience a new era of 3D molecular imaging — HCR™ Gold RNA-FISH meets Alpenglow's 3Di™ light-sheet system to reveal RNA expression in intact tissues with stunning clarity. This collaboration merges two state-of-the-art technologies into a seamless imaging solution. HCR™ Gold RNA-FISH provides highly specific and sensitive labeling of RNA targets in any sample, including thick tissues and whole-mount specimens. Additionally, the HCR™ platform's small DNA-based amplification reagents enable deep sample penetration and produce strong signals with minimal background, ensuring robust results even in challenging samples. Complementing this, Alpenglow's 3Di™ HOTLS system generates high-resolution 3D reconstructions across a broad range of sample sizes and formats, transforming labeled samples into rich, spatially resolved datasets. Alpenglow further enhances these insights with cutting-edge data processing and AI-driven analysis, enabling a deeper understanding of complex biological systems. 'HCR™ products have long enabled researchers to see deeper – delivering gold-standard performance in thick and complex samples, from whole-mount embryos to cleared tissues,' said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. 'We pioneered protease-free sample preparation to preserve fine structure, and now, with Alpenglow, we're entering a new era: democratizing 3D molecular imaging for the translational community. By combining the precision of HCR™ Gold with the power of open-top light-sheet microscopy, we're opening a window into intact biology – making it possible to explore molecular organization in its native context, at scale.' 'We are excited to work with the team at Molecular Instruments,' said Nick Reder, MD and CEO of Alpenglow Biosciences. 'With their high-quality HCR™ Gold reagents and ability to penetrate deep tissue, along with our 3Di Instrument, we will bring a powerful new tool to customers seeking to understand the underlying biology of their tissue specimens with labeling of RNA targets. These tools working together will help researchers and drug development scientists to unlock insights within the tissue to help accelerate their scientific programs.' Together, the two platforms eliminate the limitations of conventional 2D histology, which often relies on thin tissue sections and can obscure key biological context. This integrated approach empowers researchers to explore intact samples – such as embryos, organoids, and other delicate 3D structures – without disrupting their morphology. In doing so, scientists can uncover spatial patterns and cellular interactions that would otherwise be lost in serial sections. Designed for modern workflows, HCR™ Gold is fully compatible with tissue clearing and automation, ensuring reproducible, scalable performance across large studies. Alpenglow's 3Di™ HOTLS enhances this capability with a versatile imaging system that supports scan volumes up to 12.5 cm by 7 cm and features a 1 cm working distance – delivering high-throughput, adaptive imaging across diverse research applications. This joint solution is especially impactful in fields such as developmental biology, neuroscience, and immunology – areas where understanding molecular organization in 3D is critical to advancing scientific discovery. By combining the precision of HCR™ Gold with the advanced imaging capabilities of 3Di™ HOTLS, MI and Alpenglow Biosciences are offering deeper insights into complex systems and setting a new standard in molecular profiling. About Molecular Instruments Molecular Instruments® ( is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics. About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at
NZ Autocar
31-05-2025
- Automotive
- NZ Autocar
Will Alpine launch a hydrogen-powered supercar eventually?
Alpine is continuing with development of its hydrogen-powered Alpenglow concept, now evolved into the Hy4 prototype. First revealed in 2022, the Alpenglow's transformation into the Hy4 suggests Alpine is increasingly serious about hydrogen combustion technology. The Hy4, built on a Ligier LMP3 racing chassis, swaps the original single-seat layout for a more conventional two-seat set-up, suggesting a shift towards a road orientation. The Hy4 was set to debut at the World Endurance Championship in Spa-Francorchamps, Belgium. However, an electrical fault prevented that. Alpine's design chief, Antony Villain, is still optimistic. He said that the Alpenglow was always envisioned for both road and track ends. Villain added that Alpine is considering a small production run of the hydrogen-powered supercar. He stressed that both hydrogen-combustion and battery-electric technologies are being pursued at present. Development was always aimed at eventual production, he said, calling the Alpenglow more of a 'programme' than a concept. Future versions will evolve with improved styling and added everyday utility. A critical part of this update is a new V6 hydrogen engine being developed entirely in-house by Alpine. It is set to replace the existing turbocharged 2.0-litre four-cylinder sourced from motorsport partner Oreca. The new V6 should add both power and efficiency. The Hy4's range currently stands at around 100km at race pace. Le Mans racers generally run 10–20 laps of the 14km circuit before refueling so added efficiency is an imperative. Racing vehicles director François Champod stressed the engine will offer accessible, user-friendly power, unlike a high-revving F1 unit. There are still engineering challenges to overcome. Alpine's hydrogen engineer, Pierre-Jean Tardy, explained that while hydrogen combustion produces similar engine response and sound to petrol, it behaves differently. Running lean for efficiency and low NOx emissions leads to cooler exhaust gases, creating challenges for turbochargers, especially increased lag. In addition, hydrogen's wide flammability range complicates combustion control, increasing the risk of engine knock. Mixing hydrogen gas with air uniformly is another major stumbling block, especially at high engine speeds. Hydrogen is injected at very high velocities, making it harder to mix properly and increasing the risk of abnormal combustion. Temperature management within each combustion chamber must also be uniform to avoid reliability issues. Alpine acknowledges that its hydrogen-combustion technology is in its infancy. The V6 has only recently begun testing on a dynamometer. But the goal is to power the Alpenglow with hydrogen by year's end. While Alpine is eyeing entry into the hydrogen-combustion class at the 2027 Le Mans 24 Hours, it has not made a formal commitment yet. A road-going hydrogen car from Alpine remains a long-term possibility. Champod warned that the broader hydrogen infrastructure will determine its future. The current hydrogen refueling network can only support a limited number of vehicles. However, Renault Group's Hyvia venture, focused on hydrogen-powered vans, could aid infrastructure development. Trucks and light commercial vehicles (LCVs) are expected to lead the rollout of hydrogen stations, indirectly supporting niche vehicles like the Alpenglow. Fuel storage on board remains a significant challenge. Hydrogen tanks require more space than petrol equivalents—over 350 litres versus 50 litres—posing packaging problems. Moreover, Alpine insists hydrogen use must be 'clean' to justify its environmental benefits. That means only decarbonized hydrogen (with carbon capture) or green (via renewable-powered electrolysis).
Miami Herald
28-05-2025
- Automotive
- Miami Herald
Alpine to Launch 1000HP Hybrid Supercar in 2028 with Le Mans-Derived V6
Alpine, a historic French sportscar maker best known in the Americas as a Formula One and World Endurance entrant, is to launch a supercar in 2028. It will have around 1000 horsepower, says CEO Phillippe Krief. Most of that comes from a mid-mounted V6 driving the rear wheels. It's augmented by two torque-vectoring electric motors, one for each front wheel. The V6, Krief says, will be developed by the same engineers who do the Le Mans powertrain. The car will use aluminum and carbon-fiber in its construction. Alpine showed a hypercar concept called the Alpenglow three years ago, and afterward it ran, using a hydrogen-combusting V6 to explore this as a race fuel. It looked wonderful, but Krief dismisses the suggestion that the new supercar will bear a resemblance. He points out that the Alpenglow was built with the dimensions of a Le Mans car. "This will be a road car, very different." Krief was technical director at Ferrari before taking the Alpine job, so we might take him seriously when he mentions the SF90 in context of this Alpine supercar. Alpine is a member of the Renault Group, and recently launched two sporty EVs, a subcompact hot hatchback called the A290, and a fastback compact, the A390. The A390 distinguishes itself with a three-motor layout providing torque vectoring for claimed high agility. Total output is 470 hp. If you struggle to see the connection between two small EV five-doors and a hypercar, note that Alpine is launching cars to bridge the gap. For seven years, it has been building a sublime little ICE mid-engined two-seater called the A110. In 2026, a new A110 will launch. Although fully electric, it will be a true sports car. The battery pack will be split in two, some behind the two seats and some in front, to ensure the seating position is low to the road. It will use an in-wheel motor for each rear tire. Krief says vehicle mass will be about the same as a comparable piston-engine car, the Porsche Boxster. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
